Head-to-head comparison
| Property | GHRP-6 | Ipamorelin |
|---|---|---|
| Category | Muscle & Growth | Muscle & Growth |
| Legal Status | Reclassification Pending | Reclassification Pending |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~15–20 minutes (plasma) | ~2 hours |
| Mol. Weight | 872.45 Da | 711.85 Da |
| Side Effects | Intense acute hunger / appetite surge, Cortisol elevation (transient), Prolactin elevation (transient) | Headache, Flushing, Injection site pain |
Key differences
- Selectivity: Ipamorelin is the most selective GH secretagogue, with minimal effects on cortisol, prolactin, and ACTH; GHRP-6 elevates cortisol and prolactin and strongly activates the appetite pathway.
- Appetite stimulation: GHRP-6 is notorious for causing intense hunger within 20–30 minutes of injection; ipamorelin has minimal appetite effects.
- GH potency: GHRP-6 produces strong GH release, comparable to or slightly higher than ipamorelin per dose.
- Cortisol/prolactin: GHRP-6 raises cortisol and prolactin at typical doses; ipamorelin does not at standard doses.
- Side effect profile: Ipamorelin is considered one of the mildest GH peptides; GHRP-6 has more pronounced side effects including hunger, water retention, and cortisol elevation.
- Common pairing: Both are frequently combined with GHRH analogs (CJC-1295 or sermorelin). Ipamorelin + CJC-1295 is the most popular modern GH peptide stack.
- Development era: GHRP-6 was developed in the 1980s–1990s; ipamorelin was developed later with the specific goal of improving selectivity.
The verdict
Ipamorelin is the preferred choice for most GH optimization protocols due to its clean selectivity — strong GH release without cortisol, prolactin, or significant appetite effects. GHRP-6 may be preferred when appetite stimulation is desired (e.g., for underweight individuals or during recovery from illness) or when maximum raw GH output is prioritized over hormonal cleanliness. For the majority of use cases, ipamorelin's superior side effect profile makes it the default recommendation.
Frequently asked questions
GHRP-6 strongly activates the ghrelin receptor, which triggers intense appetite as a direct signaling effect. This is the same pathway that regulates natural hunger. Ipamorelin activates the same receptor class but with much greater selectivity for GH release over appetite stimulation.
GHRP-6 produces comparable or slightly higher peak GH levels than ipamorelin, but this comes with cortisol and prolactin elevation. Ipamorelin provides strong GH stimulation without these off-target effects, making it more efficient from a net benefit perspective.
Both act on the ghrelin receptor pathway, making combination somewhat redundant. A more effective strategy is pairing one (typically ipamorelin) with a GHRH analog (like CJC-1295) for synergistic GH release through complementary receptor systems.
GHRP-6 may be preferred when appetite stimulation is a desired effect — for example, in recovery from illness, injury, or in underweight individuals trying to increase caloric intake. Its intense hunger-inducing effect is a disadvantage for most users but an advantage in specific contexts.
No, ipamorelin does not significantly raise cortisol at standard doses, which is its primary advantage over GHRP-6 and other older GH releasing peptides. This selectivity makes it better suited for long-term protocols where cortisol elevation would be counterproductive.